Animalcare Group (ANCR)

Sector:

Pharma and Biotech

Index:

FTSE AIM All-Share

 260.00p
   
  • Change Today:
      0.000p
  • 52 Week High: 301.00
  • 52 Week Low: 209.00
  • Currency: UK Pounds
  • Shares Issued: 68.99m
  • Volume: 37,842
  • Market Cap: £179.37m

Animalcare Group's revenue rises while weary of Brexit vote

By Maryam Cockar

Date: Wednesday 12 Oct 2016

LONDON (ShareCast) - (ShareCast News) - Veterinary medicine supplier Animalcare Group's revenue rose while it remains cautious over the uncertainty arisen since the Brexit vote as it took measures to hedge against currency fluctuations.
For the year ended 30 June, revenue increased 8.6% to £14.7m, compared to the previous year due to the company increasing sales of licensed veterinary medicines in the UK and export markets by over £650,000 combined.

This resulted in a 2.5% rise in pre-tax profit to £3.09m with export sales rising 23%.

Chief executive Iain Menneer said the Brexit result the EU referendum would "inevitably have an impact on our business", although the extent is unclear but the timing of the result allowed it to put plans in place to incorporate the currency instability for the new financial year.

He said that the "encouraging" early progress of sales outside Europe will diversify its markets in the short-term, while subsequent changes to the European pharmaceutical regulatory framework are currently unknown.

During the year there was a "robust" increase in sales from the licensed veterinary medicines product group which reported a 7.7% rise in revenue to £9.2m.

In the companion animal identification product, revenue was up 16.1% to £2.7m, which included £300,000 from, the passing of a law in April which made it compulsory for dogs to be microchipped in England, Scotland and Wales.

Revenues from the animal welfare products range increased 5.1% to £2.78m.

Underlying operating profit climbed 2.6% to £3.2m and underlying basic earnings per share was up 3.2% to 13p.

The York-based company is debt free and reported a balance sheet with net cash of £7.1m, a 22.4% increase while cash generated from operations rose 2.2% to £4.6m.

There is a pipeline of products in development as planned investment increased 100% to £1.6m.

Menneer, said: "Whilst the animal health industry evolves with customer consolidations and supplier mergers and acquisitions we have shown that we can continue to grow organically through launching new products and providing a superior service to our customers.

"With the first products successfully through our development pipeline we will start to see early revenue growth with more significant impact in subsequent periods. More product registrations are expected in the current period."

Animalcare recommended a 6.6% increase in the dividend to 6.5p per share.

Shares in Animalcare Group were down 3.52% to 283p at 0902 BST.

Email this article to a friend

or share it with one of these popular networks:


Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

 

ANCR Market Data

Currency UK Pounds
Share Price 260.00p
Change Today 0.000p
% Change 0.00 %
52 Week High 301.00
52 Week Low 209.00
Volume 37,842
Shares Issued 68.99m
Market Cap £179.37m

ANCR Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
91.77% below the market average91.77% below the market average91.77% below the market average91.77% below the market average91.77% below the market average
80.49% below the sector average80.49% below the sector average80.49% below the sector average80.49% below the sector average80.49% below the sector average
Price Trend
45.55% above the market average45.55% above the market average45.55% above the market average45.55% above the market average45.55% above the market average
63.64% above the sector average63.64% above the sector average63.64% above the sector average63.64% above the sector average63.64% above the sector average
Income
86.03% below the market average86.03% below the market average86.03% below the market average86.03% below the market average86.03% below the market average
66.67% below the sector average66.67% below the sector average66.67% below the sector average66.67% below the sector average66.67% below the sector average
Growth
11.89% above the market average11.89% above the market average11.89% above the market average11.89% above the market average11.89% above the market average
10.34% below the sector average10.34% below the sector average10.34% below the sector average10.34% below the sector average10.34% below the sector average

What The Brokers Say

Strong Buy 1
Buy 2
Neutral 1
Sell 0
Strong Sell 0
Total 4
buy
Broker recommendations should not be taken as investment advice, and are provided by the authorised brokers listed on this page.

ANCR Dividends

  Latest Previous
  Final Interim
Ex-Div 19-Jun-25 17-Oct-24
Paid 18-Jul-25 15-Nov-24
Amount 3.00p 2.00p

Trades for 29-Aug-2025

Time Volume / Share Price
13:55 17,985 @ 260.90p
16:02 500 @ 261.00p
14:13 5 @ 259.12p
12:48 217 @ 259.12p
12:36 712 @ 260.90p

ANCR Key Personnel

CFO Chris Brewster
CEO Jenny Winter

Top of Page